@article{83fd2ea616ab448998c0b044e831a820,
title = "Prospective Multicenter Experience With Cooled Radiofrequency Ablation Using High Impedance Irrigant to Target Deep Myocardial Substrate Refractory to Standard Ablation",
abstract = "Objectives: This study sought to evaluate the efficacy and safety of using half-normal saline (HNS) as the cooling radiofrequency ablation (RFA) irrigant among patients who had failed prior, standard RFA. Background: Effective control of ventricular arrhythmias that arise from mid-myocardium may be refractory to standard RFA. Recent data suggest that delivering fluid with decreased ionic concentration during open-irrigated RFA can produce deeper RFA lesions. Methods: A 12-center prospective analysis was performed of all ablations using HNS for the treatment of ventricular arrhythmias (premature ventricular complex [PVC]/ventricular tachycardia [VT]) refractory to standard ablation with normal saline irrigant. Results: HNS RFA was used clinically to target 94 PVC/VTs refractory to standard ablation. Acute success was achieved in 78 of 94 (83%), with longer-term success occurring in 78 subjects after a mean follow-up of 6.1 ± 6.7 months (range, 3.0 to 25.2 months). Steam pops were observed among 12 (12.6%) patients. There were no significant changes in electrolytes measured before and after the use of HNS, and there were no complications related to HNS use. Conclusions: The use of HNS instead of normal saline irrigant during high-power delivery targeting deep myocardial substrate is safe and effective. PVC/VT sources previously unaffected by standard ablation may be successfully ablated with improved efficiency of radiofrequency delivery using HNS.",
keywords = "ablation, radiofrequency, ventricular arrhythmias",
author = "Nguyen, {Duy T.} and Tzou, {Wendy S.} and Amneet Sandhu and Carola Gianni and Elad Anter and Roderick Tung and Miguel Valderr{\'a}bano and Patrick Hranitzky and Kyoko Soeijma and Luis Saenz and Garcia, {Fermin C.} and Tedrow, {Usha B.} and Miller, {John M.} and Gerstenfeld, {Edward P.} and Burkhardt, {J. David} and Andrea Natale and Sauer, {William H.}",
note = "Funding Information: Drs. Sauer and Nguyen have received grants from Biosense Webster, CardioNXT, St. Jude Medical, Boston Scientific, and Medtronic; have a provisional patent on partially insulated focused catheter ablation; and have non-public equity interests/stock options in CardioNXT. Dr. Tzou has received personal fees from Boston Scientific, Medtronic, Biosense Webster, and Abbott. Dr. Anter has received personal fees from Biosense Webster and Boston Scientific. Dr. Valderr{\'a}bano has received grants from Circa Scientific and Biosense Webster; and has received personal fees from Biosense Webster, Boston Scientific, and Abbott. Dr. Soejima has received personal fees from Abbott Japan. Dr. Tedrow has received personal fees from Abbott, Biosense Webster, Boston Scientific, and Medtronic. Dr. Miller has received personal fees from Medtronic, Boston Scientific, Biotronik, Abbott Electrophysiology, and Biosense Webster. Dr. Gerstenfeld has received grants and personal fees from Biosense-Webster and St Jude Medical; and has received personal fees from Boston Scientific. Dr. Burkhardt has received personal fees from Biosense Webster and Stereotaxis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: {\textcopyright} 2018 American College of Cardiology Foundation",
year = "2018",
month = sep,
doi = "10.1016/j.jacep.2018.06.021",
language = "English (US)",
volume = "4",
pages = "1176--1185",
journal = "JACC: Clinical Electrophysiology",
issn = "2405-500X",
publisher = "Elsevier",
number = "9",
}